Diagnostic Test of PIVKA-II as A Tumor Marker for Hepatocellular Carcinoma

Dwi Priyadi Djatmiko, I Putu Adi Santosa, Elvin Richela Lawanto, Bogi Pratomo, Hani Susianti


Alpha-Fetoprotein (AFP) is a tumor marker that has been widely used for HCC, but there has been no increased AFP in
35-45% patients with HCC. Protein induced by vitamin K absence or antagonist II (PIVKA-II) is abnormal prothrombin
secreted in HCC and is expected to be used as a diagnostic marker of HCC. The objective of this study was to compare serum
PIVKA-II levels in the patients with HCC, cirrhosis, and healthy control and determine the diagnostic value of PIVKA-II for
hepatocellular carcinoma. This was a cross-sectional, analytical observational study to identify the diagnostic value of
PIVKA-II for HCC diagnosis. The diagnosis of 20 cirrhotic patients and 15 patients with HCC was established by using medical
history, physical examination, and additional tests according to the diagnosis criteria. A group of 12 individuals with normal
liver function was used as healthy control subjects. Serum PIVKA-II levels were analyzed with the immunoassay method. For
the comparison study, the independent-samples Kruskal Wallis test was used. Also, to determine sensitivity, specificity,
positive and negative predictive value (PPV and NPV), ROC curve analysis, and 2x2 contingency table was used. The serum
PIVKA-II levels in the patients with HCC were significantly higher than in cirrhotic patients (p=0.000) and healthy control
(p=0.000). Sensitivity, specificity, PPV, and NPV of PIVKA-II for diagnosis of HCC in cirrhotic patients at a cut-off value of
140.85 mAU/mL were 93.33%, 75%, 73.68%, and 93.75%, respectively (AUC=0.87).PIVKA-II had a high diagnostic value for
HCC diagnosis. Diagnostic tests that compare serum PIVKA-II levels in any size of HCC nodules might be needed in the


PIVKA-II, AFP, hepatocellular carcinoma, diagnosis

Full Text:



Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology, Best Practice & Research Clinical Gastroenterology 2014; 28(5): 753 - 70.

Health Ministry of The Republic of Indonesia. Stop Cancer. Jakarta, Data and Information Center, 2015; 1 - 6.

Health Ministry of The Republic of Indonesia. Hepatitis Situation and Analysis. Jakarta, Data and Information Center, 2014; 1 - 6.

Zhu R, Yang J, Xu L, Dai W, Wang F, Shen M, et al. Diagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma: A meta-analysis. Gastroenterology Research and Practice 2014.

Zhang YS, Chu JH, Cui SX, Song ZY, Qu XJ. Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma. Cellular Physiology and Biochemistry 2014; 34(3): 903 - 15.

Norsa’adah, Bachok, Nurhazalini-Zayani, Che Ghazali Che. Epidemiology and Survival of Hepatocellular Carcinoma in North-east Peninsular Malaysia. Asian Pacific Journal of Cancer Prevention 2013; 14(11): 6955-59.

Keng VW, Largaespada DA, Villanueva A. Why men are at higher risk for hepatocellular carcinoma? Journal of hepatology 2012; 57(2): 453 – 4.

Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison’s Principles of Internal Medicine. 19th Ed., New York, McGraw-Hill Education, 2015; 2058.

Kirstein, MM. Vogel, A. The pathogenesis of hepatocellular carcinoma. Digestive Diseases 2014; 32(5): 545 - 553.

Murata, K., Suzuki, H., Okano, H., Oyamada, T., Yasuda, Y. and Sakamoto, A. Hypoxia-induced des-γ-carboxy prothrombin production in hepatocellular carcinoma. International journal of oncology 2010; 36(1): 161-170.

Zakhary NI, Khodeer SM, Shafik HE, Malak CAA. Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. Journal of Advanced Research 2013; 4: 539 - 546 .

DOI: http://dx.doi.org/10.24293/ijcpml.v26i2.1436


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.